P&G to Acquire Thorne for $3.8 Billion, Betting on Science-Backed Supplements
The world's largest consumer goods company is buying its way deeper into personalized health, taking practitioner-trusted supplement brand Thorne off private equity's hands in an all-cash deal that underscores how mainstream the wellness category has become.
The Deal at a Glance
Procter & Gamble (NYSE: PG) announced on August 4, 2026, that it has entered into a definitive agreement to acquire Thorne, the science-backed supplement and testing company, from private equity firm L Catterton in an all-cash transaction valued at $3.8 billion. L Catterton, the LVMH-backed consumer investment firm that took Thorne private in 2023 for $680 million, said the deal is expected to close in the fourth quarter of 2026, pending customary regulatory approvals.
P&G Chief Executive Shailesh Jejurikar disclosed the pending transaction during a CNBC appearance ahead of the formal announcement, framing it as part of the company's push to expand its beauty and wellness footprint through acquisitions. Reports from the Financial Times had earlier named UK-based Haleon and Unilever as other parties reportedly weighing a bid for Thorne, underscoring how contested the asset had become.
Key Takeaways
- P&G will pay $3.8 billion in cash for Thorne, more than 5.5 times the price L Catterton paid to take the company private less than three years ago.
- The deal expands P&G's existing health portfolio — which includes Metamucil, Align Probiotic and New Chapter — with a practitioner-facing, vertically integrated supplement brand.
- Thorne, founded in 1984 and based in Summerville, South Carolina, manufactures its own products and is used by tens of thousands of healthcare practitioners and over seven million consumers.
- Thorne's total sales were reported by CNBC to be tracking toward roughly $650 million in 2026, with the majority of revenue coming from shoppers under 40.
- For Gulf markets, the deal signals accelerating consolidation in a nutritional-supplements category that is projected to keep growing at high single- to double-digit rates through the next decade.
From Practitioner Brand to Private Equity Exit
Thorne's path to this deal has moved quickly. The company went public on Nasdaq in late 2021 at a valuation of roughly $525 million, built around a reputation for clinical rigor, biometric testing, and a research collaboration with the Mayo Clinic. L Catterton took it private in December 2023 for $680 million, installing former Vitamin Shoppe chief executive Colin Watts to lead the core supplement and testing business while pursuing a strategy built on the shift toward proactive, clinically informed self-care.
That strategy appears to have paid off. In under three years, L Catterton has more than quintupled its entry valuation — a return that reflects both operational improvements at Thorne and a broader repricing of the vitamins, minerals and supplements category as strategic buyers compete for scarce, credible assets.
-"We are really happy with the asset itself. It's a really well-run operation, and it's been around for a long time."
Why P&G Is Buying Into Supplements Now
The acquisition strengthens P&G's Personal Health Care division at a moment when demand for preventative and personalized wellness continues to climb in the United States, amplified by a policy and cultural environment — including the "Make America Healthy Again" movement associated with Health and Human Services Secretary Robert F. Kennedy Jr. — that has pushed supplements further into the mainstream. P&G already owns Metamucil, Align Probiotic and New Chapter within a healthcare unit that spans Oral-B and Vicks; Thorne adds a higher-end, practitioner-endorsed brand with its own manufacturing base rather than a licensed or contract-made portfolio.
Thorne's leadership has framed the deal as continuity, not a change of mission — describing P&G as sharing its commitment to science, quality and consumer trust, with day-to-day operations and standards unaffected while the transaction moves toward close.
Thorne, company statement, August 4, 2026Part of a Broader Consolidation Wave
P&G's move follows a pattern among large consumer goods companies acquiring their way into the vitamins, minerals and supplements category rather than building organically. Unilever acquired gummy-supplement brand Grüns earlier in 2026, and Haleon and Unilever were both reportedly in the running for Thorne before P&G prevailed. The common thread is a belief that owning a credible, science-anchored brand is faster and less risky than building practitioner trust from scratch — particularly as regulatory scrutiny of supplement marketing claims increases across major markets.
Implications for the MENA Region
Saudi Arabia's nutritional supplements market has been expanding at a mid-to-high single-digit compound annual rate, with multiple industry estimates placing 2025 market size in the $4–4.6 billion range and projecting continued double-digit growth in dietary-supplement sub-segments through 2030, supported by Vision 2030's preventive-health agenda and streamlined Saudi Food and Drug Authority approval pathways. Widely cited deficiency data — including reported vitamin D deficiency affecting a majority of the population — has kept fortified and clinically framed supplement categories, precisely where Thorne is positioned, among the fastest-growing segments regionally.
A larger, better-capitalized owner behind a science-first supplement brand could accelerate its entry or expansion into Gulf retail and e-commerce channels, where international premium wellness brands have been gaining share. For regional distributors, pharmacies and health-tech platforms, the deal is a signal that global consumer goods majors see personalized, practitioner-endorsed nutrition as a durable growth category worth premium prices — a thesis that applies as directly to Riyadh and Jeddah as it does to the U.S. market where Thorne was built.
Editorial View
This deal is less about Thorne itself than about what large strategics are now willing to pay for credibility in wellness. A 5.6x return for L Catterton in under three years is a strong signal that consumer giants view science-backed, practitioner-trusted supplement brands as scarce and worth acquiring at a premium, even as regulatory and reputational risk around health claims continues to rise. For MENA operators and investors watching the category, the message is similar to what played out in food ingredients earlier this year: consolidation is accelerating, and credibility — not just scale — is what commands the multiple.
